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Background. Variables associated with the outcome of patients treated for prosthetic joint infections (PJIs) due
to Staphylococcus aureus are not well known.
Methods. The medical records of patients treated surgically for total hip or knee prosthesis infection due to S.
aureus were reviewed. Remission was deﬁned by the absence of local or systemic signs of implant-related infection
assessed during the most recent contact with the patient.
Results. After a mean posttreatment follow-up period of 43.6 6 32.1 months, 77 (78.6%) of 98 patients were in
remission. Retention of the infected implants was not associated with a worse outcome than was their removal.
Methicillin-resistant S. aureus (MRSA)–related PJIs were not associated with worse outcome, compared with
methicillin-susceptible S. aureus (MSSA)–related PJIs. Pathogens identiﬁed during revision for failure exhibited no
acquired resistance to antibiotics used as deﬁnitive therapy, in particular rifampin. In univariate analysis,
parameters that differed between patients whose treatment did or did not fail were: American Society of
Anesthesiologists (ASA) score, prescription of adequate empirical postsurgical antibiotic therapy, and use of
rifampin combination therapy upon discharge from hospital. In multivariate analysis, ASA score #2 (odds ratio
[OR], 6.87 [95% conﬁdence interval {CI}, 1.45–32.45]; P 5 .04) and rifampin-ﬂuoroquinolone combination
therapy (OR, 0.40 [95% CI, 0.17–0.97]; P 5 .01) were 2 independent variables associated with remission.
Conclusions. The results of the present study suggest that the ASA score signiﬁcantly affects the outcome of
patients treated for total hip and knee prosthetic infections due to MSSA or MRSA and that rifampin combination
therapy is associated with a better outcome for these patients when compared with other antibiotic regimens.
Prosthetic joint infections (PJIs) represent a growing
public health concern in developed countries as a result
of the increasing number of operations for total joint
arthroplastyand a riskofpostoperative infection of 1%–
2% [1, 2]. Such infections are associated with substantial
morbidity, increased medical costs, and reduced quality
of life [3, 4]. General principles of management of PJI
include a multidisciplinary approach at centers with
expertiseinthisﬁeld.Reliablemicrobiologicaldiagnosis,
along with surgical procedures ranging from prosthesis
removal with or without reimplantation to debridement
with implant retention, and prolonged appropriate an-
tibiotic therapy, are key elements in the management of
such infections. Factors inﬂuencing the outcomes of
patients with PJI have been assessed in previous studies
and include retention of infected material, duration of
symptoms of infection, and bacterial resistance [5–8].
However, the role of these parameters differs from one
study to another and is related to study design, patients
included, type of surgery, posttreatment follow-up du-
ration, the pathogens in question, and the deﬁnition of
cure. Although most PJIs are caused by Staphylococcus
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treatment of early postoperative PJIs or combining coagulase-
negative staphylococci (CNS) and S. aureus PJIs, have assessed
variables associated with outcome [9–16]. The purpose of the
present retrospective study was therefore to identify variables
associatedwithoutcomeinalargeseriesofpatientstreatedforS.
aureus PJIs, treated according to an algorithm derived from the




This was a retrospective study of an observational cohort of
patients treated for a PJI due to S. aureus. We compared char-
acteristics of patients according to outcome. Patients were ob-
served from initial surgical procedure for infection to most
recent contact.
Study Population
All patients treated surgically for PJI due to S. aureus (mono- or
polymicrobial infection) at our institution, which is currently 1
of 8 French reference centers for osteoarticular infections, were
identiﬁed by searching the database of the microbiology labo-
ratory for the items ‘‘S. aureus’’ and ‘‘total hip or knee pros-
thesis.’’ The study was approved by the institutional review
boards of both Dron and Roger Salengro hospitals.
Definitions
PJI due toS.aureuswas deﬁnedastheisolationof$1st ra inofS.
aureus from a reliable sample taken from the prosthetic site.
Histological examination was not used in the present study,
because this technique is not performed routinely at our in-
stitution. The term ‘‘polymicrobial infection’’ was used when
different bacterial species were simultaneously identiﬁed from
samples. ‘‘Time to infection’’ was deﬁned as time from im-
plantation of the prosthesis to clinical onset of infection and was
categorized into early (#3 months after implantation), delayed
(.3t o,24 months after implantation), or late ($24 months
after implantation) infection. Acute or chronic PJI was deﬁned
as time from initiation of symptoms of infection to diagnosis
lasting for, respectively, ,1a n d.1 month. Empiric post-
operative antibiotic therapy was deﬁned as adequate if it con-
tained $1 antibiotic agent active against the pathogen(s)
identiﬁed in the intraoperative samples. Antibiotic treatment
based on results of intraoperative sample culture was called
‘‘deﬁnitive antibiotic therapy.’’ Remission was deﬁned by the
absence oflocalorsystemicsignsofinfectionassessedduringthe
most recent contact with the patient and absence of the need to
reoperate or to administer antibiotic therapy directed to the
initial infected site from the end of treatment to the most recent
contact. Failure was deﬁned as any other outcome, including
death related to the PJI. We focused the paper on infection
eradication recurrence rather than on functional assessment
because of the different orthopedic situations seen in our pop-
ulation of patients for whom assessing the functionality may
have introduced imprecision for distinguishing patients in
remission from those whose treatment failed.
Medical and Surgical Therapy
Medical and surgical management of each patient followed an
algorithm derived from the experience reported by Zimmerli
et al and several other authors [17–23]. Debridement with re-
tention was used for patients with early postoperative or acute
hematogenous infection and no implant loosening, if the du-
ration of clinical signs and symptoms was ,4 weeks and if soft
tissues surrounding the prosthetic site were in good condition.
In the other cases, 1-stage exchange was performed in non-
immunocompromised patients having reliable preoperative
microbiological information and satisfactory soft tissue. Two-
stage exchange was preferred for non-immunocompromised
patients whose soft tissue was damaged or for whom reliable
preoperative bacterial information was unavailable. Both ar-
throplastic resection and arthrodesis were performed in severely
immunocompromised patients or in those in whom joint
replacement would not have resulted in functional beneﬁt. For
2-stage procedures (ie, 2-stage replacement and arthrodesis),
reimplantation was performed after an antibiotic treatment
duration of $12 weeks with or without an additional antibiotic-
free period of 4 weeks and if the C-reactive protein value had
normalized (,10 mg/L), except when chronic inﬂammatory
disease interfered with C-reactive protein values. A spacer was
used in patients treated with 2-stage replacement of the pros-
thesis, even in case of methicillin-resistant S. aureus (MRSA)
infection, which was the only situation that differed from the
recommendations of Zimmerli et al [1]. After reimplantation of
a new prosthesis or arthrodesis, the duration of antibiotic
therapy depended on results of intraoperative sample cultures
(ie, 2 weeks in case of negative culture results if antibiotic
therapy had been stopped $2 weeks prior to the intervention,
and 6–12 weeks in case of positive culture results). Therapeutic
strategy was decided for each patient at a multidisciplinary
meeting of orthopedic surgeons, infectious disease consultants,
microbiologists, and anesthesiologists. In each case, the patient
was aware of the different therapeutic options and took part in
the ﬁnal decision. All surgical procedures were performed
without antibiotic prophylaxis. A combination of antimicrobial
agents administered intravenously was begun intraoperatively
immediately after samples were taken. It consisted of a broad-
spectrum b-lactam agent (eg, cefotaxime, aztreonam, or imi-
penem) and a second antimicrobial agent with activity against
methicillin-resistant staphylococci (vancomycin, teicoplanin, or
linezolid). This treatment was continued until microbiological
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then modiﬁed on the basis of culture results. Antibiotics were
selected on the basis of patient comorbidity and prescribed at
doses adaptedfrom those proposed byZimmerliet al[1], except
for rifampin, the daily dose of which was 20 mg/kg administered
in divided doses given twicea day, without exceedingdaily doses
of 1800 mg. After discharge from hospital, the patient was
followed up by both the referring surgeon and the infectious
disease consultant 1 month after discharge and at the end of
antibiotic treatment.The totaldurationofantimicrobialtherapy
was 3–6 months, as proposed by Zimmerli et al [1]. Patients
were then followed up by their referring surgeon once a year for
a minimum of 2 years. Missing data on patient outcome after
the end of antibiotic treatment were obtained by telephone
contact with the patient himself/herself or the general practi-




2 test was used to compare qualitative variables
and a 2-sample t test to compare continuous variables. A P value
of ,.05 wasconsidered toreveala signiﬁcant difference. Logistic
regression was used to identify independent variables associated
with failure. Variables with medical or biological meaning were
retained for the multivariate analysis when their effect had
a P value less than .25. We constructed a receiver operating
curve (ROC) to assess the validity of the model. Statistical
analysis was performed using STATA, version 7.0 (StataCorp).
RESULTS
Study Population
Ninety-eight patients with PJI (71 total hip and 27 total knee
prosthesis) due to S. aureus observed at our institution during
the period from 2000 through 2006 were included in the study.
The main characteristics of the study population are pre-
sented in Table 1. Radiographic abnormalities consistent with
diagnosis of PJI were present in 54 patients (55.1%) at the time
of the ﬁrst revision, including 46 patients with implant loosen-
ing.
Microbiological Findings
Microbiological results are highlighted in Table 1. S. aureus was
identiﬁed as the sole bacterium isolated from samples taken
during the ﬁrst revision in 71 cases (72.4%) and in association
with other bacterial strains in 27 cases (27.6%), including CNS
in 13 cases (13.2%) and gram-negative bacilli in the other 14
cases (14.3%). MRSA was identiﬁed in 17 cases (17.3%), and all
these strains were susceptible to rifampin, linezolid, teicoplanin,
and vancomycin. A mean of 6.6 6 3.6 samples were taken in-
traoperatively, including 4.6 6 3.6 showing positive culture
results. Of the21patientswhose treatmentfailed, bacteriological
data were available for 18. Sixteen patients experienced relapsing
infections, which were due to S. aureus in 11 cases (methicillin-
susceptible S. aureus [MSSA] 5 6, MRSA 5 5) and CNS in the 5
other cases. The 2 other patients had a reinfection due to
Staphylococcus epidermidis. All the strains identiﬁed in these 18
patients were sensitive initially and at recurrence to rifampin
and to the other antibiotics prescribed to the patients.
Surgical and Medical Treatment
Surgical procedures and antibiotic regimens are presented
in Tables 2 and 3. For 34 patients who underwent 2-stage sur-
gical procedures (ie, 2-stage replacement and arthrodesis),
a gentamicin-loaded cement spacer was implanted for a mean
time between initial and second intervention of 116.6 6 14.9
days (range, 26–395 days). Patients with MRSA-related in-
fections were treated with removal of all the infected implants in
the same proportion as were patients with MSSA infections (11
[64.7%] of 17 vs 46 [56.8%] of 81; P 5 .74). Empiric post-
operative intravenous antibiotic therapy was administered for
a mean duration of 7.20 6 4.93 days and was concordant with
our algorithm in 65 patients (66.3%). Antibiotic regimens for
MRSA infections were a combination of rifampin plus pristi-
namycin (n 5 5), levoﬂoxacin (n 5 3), fusidic acid (n 5 1), and
teicoplanin(n51),andmonotherapywithclindamycin(n53)
or linezolid (n 5 4). Rifampin-ﬂuoroquinolone combinations
were not prescribed because of polymicrobial infection in-
volving resistant bacteria in 27 cases and allergic reactions or
intolerance in 32 cases. A total of 6 patients were given long-
term suppressive antibiotic therapy for a mean duration of
661.2 6 157.6 days. All these patients had been treated with
the debride-retain strategy and were given oral doxycycline
200 mg in 1 daily dose.
Outcome and Prognostic Factors
Aftera meanposttreatmentfollow-upof43.66 32.1months, 77
patients (78.6%) were considered to be in remission. The mean
delay from the end of treatment to the time of diagnosis of
failure was 5.5 6 4.4 months (range, 1–20; median, 5.5).
Fourteen patients (14.3%) died from causes unrelated to PJI
during a mean posttreatment follow-up of 15.8 6 10.8 months
(causes of death included malignancy in 6 patients, myocardial
infarction in 4,pulmonary embolism in 2, and pneumoniain 2).
Characteristics of treatment and outcome of patients are
presented in Tables 2 and 3. Debridement-retention and 1- or
2-step exchange procedures were associated with similar
remission rates (32 [78.0%] of 41 for debridement-retention, 14
[100%] of 14 for 1-step exchange, and 22 [84.6%] of 26 for
2-step exchange), whereas both arthroplastic resection and
arthrodesis were associated with lower remission rates than the
other procedures (4 [44.4%] of 9 and 5 [62.5%] of 8,
respectively; P 5 .02]. The overall treatment failure rate for
patients treated with retention, compared with removal of
336 d CID 2011:53 (15 August) d Senneville et alinfected implants, was similar (Table 2). No patients had to be
amputated during treatment and follow-up. The treatment
failure rate was 19.7% (16 of 81) in MSSA-infected patients and
29.4% (5 of 17) in MRSA-infected patients (P 5 .38), whereas
patients with polymicrobial infections had a 33.3% rate of
treatment failure (Table 1). Patients with polymicrobial in-
fection were treated with rifampin combinations in a signiﬁ-
cantly lower proportion than were patients with monomicrobial
Table 1. Baseline Characteristics of 98 Patients With Total Hip or Knee Prosthesis Infection Due to Staphylococcus aureus According to
Outcome
Characteristic Remission (n 5 77) Failure (n 5 21) P
Age, mean years 6 SD 66.3 6 14.7 70.0 6 13.4 .29
Male sex 32 (41.6) 11 (52.4) .38
Body mass index, mean 6 SD 28.4 6 5.7 28.3 6 7.9 .95
Diabetes mellitus 24 (31.2) 8 (38.1) .54
Use of steroid therapy 10 (12.9) 1 (4.8) .29
Ongoing cancer treatment 4 (5.2) 1 (4.8) .63
Concomitant Staphylococcus aureus bacteremia 15 (19.5) 3 (14.3) .82
Acute infection (,4 weeks duration) 14 (19.7) 6 (28.5) .36
Time to infection
Median months 6 SD 74.1 6 83.4 63.3 6 91.5 .20
Early (#3 months) 26 (33.8) 11 (52.4) .12
Delayed (.3–24 months) 17 (22.1) 4 (19.1) .76
Late ($24 months) 34 (44.1) 6 (28.5) .20
No. of operations since implantation, mean 6 SD 1.10 6 1.95 1.71 6 2.88 .94
Fever (temperature, .38C) at admission 10 (12.9) 3 (14.3) .87
Presence of sinus tract 27 (35.1) 11 (52.4) .14
White blood cell count, mean 310
9 cells/L 6 SD 9276.7 6 3647.7 8950.5 6 3452.1 .71
CRP level, mean mg/L 6 SD
At ﬁrst presentation 98.5 6 87.3 81.0 6 66.2 .39
Prior to reimplantation 18.8 6 5.9 24.16 37.1 .69
ASA score .2
a 23 (29.9) 13 (61.9) .02
Methicillin-susceptible S. aureus 65 (84.4) 16 (76.2) .38
Methicillin-resistant S. aureus 12 (15.6) 5 (23.8) .38
Polymicrobial infection 18 (25.4) 9 (42.8) .08
Coagulase-negative staphylococci 9 (11.7) 5 (23.8) .16
Other bacteria
b 9 (11.7) 4 (19.1) .42
NOTE. Data are no. (%) of patients unless otherwise indicated. ASA, American Society of Anesthesiologists; CRP, C-reactive protein; SD, standard deviation.
a Chronic diseases of the heart (n 5 2), liver (n 5 17), or kidney (n 5 4), and respiratory insufﬁciency (n 5 6) mostly related to chronic obstructive pulmonary
disease.
b Streptococcus viridans (n 5 5), Enterococcus faecalis (n 5 2), Escherichia coli (n 5 3), Pseudomonas aeruginosa (n 5 2), Propionibacterium acnes (n 5 1).
Table 2. Characteristics of Surgical Procedures and Antibiotic Therapy in 98 Patients With Total Hip or Knee Prosthesis Infection Due to
Staphylococcus aureus According to Outcome
Characteristic Remission (n 5 77) Treatment failure (n 5 21) P
Delay from onset of infection to revision, mean days 6 SD 119.4 6 238.2 79 6 111.7 .80
Removal of all infected implants 45 (58.4) 12 (57.1) .99
Gentamicin-loaded cement spacer
a 27 (35.1) 7 (33.3) .84
Adequate empirical postsurgical antibiotic therapy
b 73 (94.8) 17 (80.9) .04
Rifampin-ﬂuoroquinolone combination therapy 37 (48.1) 2 (9.5) .001
Rifampin combination therapy 58 (75.3) 10 (47.6) .002
Total duration of antibiotic therapy, mean days 6 SD 165.7 6 108.8 145.1 6 101.6 .44
NOTE. Data are no. (%) of patients unless otherwise indicated. SD, standard deviation.
a Including 26 patients with 2-stage replacement and 8 with arthrodesis.
b At least 1 antibiotic agent active against intraoperative pathogen(s).
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In univariate analysis, parameters that differed between
patients whose treatment did or did not fail were American
Society of Anesthesiologists (ASA) score and prescription of
adequate empirical postsurgical antibiotic therapy and rifam-
pin combination therapy upon discharge from the hospital
(Table 1). Among the systemic diseases that allocated patients
to ASA score .2, chronic liver disease including cirrhosis was
signiﬁcantly more frequent in patients with treatment failure
than in those with remission (8 of 21 vs 9 of 77; P 5 .01). ASA
score .2 was signiﬁcantly less frequent in patients treated with
rifampin-ﬂuoroquinolone than in patients treated with other
antibiotic regimens (Table 4). In multivariate analysis, an
ASA score #2 (odds ratio [OR], 6.87 [95% conﬁdence interval
{CI}, 1.45–32.45]; P 5 .04) and the use of rifampin-
ﬂuoroquinolone combination therapy (OR, 0.40 [95% CI,
0.17–0.97]; P 5 .01) were 2 independent variables associated
with remission. We assessed the sensitivity and speciﬁcity of
the model by means of an ROC curve with an area under the
curve of 0.76, which showed that the model was valid. Figure 1
shows the Kaplan-Meier plot of disease-free survival in the 98
patients according to the deﬁnitive antibotic treatment (ie,
rifampin-ﬂuoroquinolone combination versus other antibiotic
regimens).
DISCUSSION
We report the outcome of 98 patients treated for total hip or
knee PJI due to S. aureus following a deﬁned algorithm derived
from experiments reported by Zimmerli et al and several other
authors [1, 17–23]. After a mean posttreatment follow-up pe-
riod of .3 years, remission of infection was observed in 77
patients (78.6%), consistent with previous studies in this area,
despitea higherproportionofimmunocompromisedpatientsin
our study [12–16]. This characteristic of our patient population
may explain the high proportion of late postoperative PJI as-
sociated with concomitant S. aureus bacteremia reported here.
One-stage replacement was associated with a better outcome
than that of other surgical procedures, including 2-stage re-
placement. The favorable conditions required for 1-stage re-
placement may explain the good results observed in our patients
who underwent this surgical procedure. Arthroplastic resection
was the surgical procedure associated with the worst outcome in
ourcohortofpatients,withafailurerateof55.6%(5of9).These
results suggest that, even in case of deﬁnitive removal of all
infected material in this population of patients (ie, severely
immunocompromised patients or those in whom joint re-
placement would not have resulted in functional beneﬁt), the
infection may not be eradicated. Overall, the comparable
Table 3. Characteristics of Treatment and Outcome of 98 Patients With Total Hip or Knee Prosthesis Infection Due to Staphylococcus
aureus
Variable
Rifampin treatment (n 5 68) No Rifampin treatment (n 5 30)
P
Fluoroquinolone
combinations (n 5 39)
Other rifampin
combinations (n 5 29)
Linezolid
monotherapy (n 5 11)
Other
treatment (n 5 19)
Debridement-retention (n 5 41) 15/16 (93.8) 10/15 (66.7) 3/3 (100) 4/7 (57.1) .11
One-stage replacement (n 5 14) 6/6 (100) 5/5 (100) 1/1 (100) 2/2 (100) .
Two-stage replacement (n 5 26) 12/12 (100) 6/9 (66.7) 4/4 (100) 0/1 (0) .01
Arthroplastic resection (n 5 9) 1/1 (100) 0 1/3 (33.3) 2/5 (40) .
Arthrodesis (n 5 8) 3/4 (75) 0 0 2/4 (50) .
Total 37/39 (94.8) 21/29 (72.4) 9/11 (81.8) 10/19 (52.6) .002
NOTE. Data are proportion (%) of patients with remission.
Table 4. Characteristics and Outcome of 98 Patients With Total Hip or Knee Prosthesis Infection Due to Staphylococcus aureus
According to the Antibiotic Treatment
Variable
Fluoroquinolone
combination (n 5 39)
Other rifampin
combinations (n 5 29)
Linezolid
monotherapy (n 5 11)
Other
treatment (n 5 19) P
Age, mean years 6 SD 68.8 6 13.9 66.7 6 14.2 64.5 6 14.4 62.1 6 17.2 .75
ASA score .2 8 (20.5) 12 (41.4) 4 (36.4) 12 (63.1) .02
MRSA 3 (7.7) 7 (24.1) 4 (36.3) 3 (15.8) .10
8 (20.5) 6 (20.7) 5 (45.4) 8 (42.1) .14
NOTE. Data are no. (%) of patients with remission unless otherwise indicated. ASA, American Society of Anesthesiologists; MRSA, methicillin-resistant
S. aureus; SD, standard deviation.
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retention or removal of infected implants conﬁrms the validity
of recommendations proposed by experts over the last 2 decades
[1, 17–23]. The large majority of patients with chronic late
postoperative infection included in the study probably explains
why the delay from onset of infection to revision did not in-
ﬂuence patient outcomes.
In the present study, the ASA score was an independent
variable associated with patient outcome, consistent with results
of a recent study of patients with group B streptococcal pros-
thetic hip infections reported by Zeller et al [24]. We also found
that use of rifampin-ﬂuoroquinolone combinations as deﬁni-
tive antibiotic therapy was another independent factor associ-
ated with remission of PJI due to S. aureus. The efﬁcacy of
a rifampin-containing regimen in patients with staphylococcal
orthopedic implant–associated infection has also been reported
in more recent observational studies [7, 25–28], conﬁrming
initial experimental model studies [29]. In our series of patients
treated in the majority of cases with rifampin combinations, we
found a trend toward higher failure rate only in patients with
MRSA infections, compared with those with MSSA infections
(29.4% and 19.7%, respectively), but this may be related to the
small size of the studied population. Salgado et al described
a signiﬁcant poor outcome associated with MRSA infections in
a series of patients treated with vancomycin without rifampin as
the main treatment [30]. Nonetheless, rifampin associated with
such antibiotics as fusidic acid [13, 15, 31], levoﬂoxacin [7, 32],
vancomycin or linezolid [34], and clindamycin or linezolid
[31] has been associated with similar failure rates between
MRSA- and MSSA-related PJIs. In the present study, patients
with polymicrobial infections experienced the highest rate of
treatment failure (33.3%) and also received rifampin treatment
in a signiﬁcantly lower proportion than did patients with
monomicrobial S. aureus infection. All these data support the
concept that rifampin is essential for the treatment of S. aureus–
related PJIs. Use of rifampin for staphylococcal infections may
be limited by the emergence of rifampin-resistant mutants, al-
though this was not observed in our patients. According to our
protocol of antibiotic therapy for PJI, rifampin was not ad-
ministered as empirical therapy but exclusively as deﬁnitive
antibiotic therapy consisting of a combination of 2 agents active
against the pathogen(s) identiﬁedin intraoperative samples.The
aim of this restriction in rifampin prescription is to prevent
rifampin monotherapy for S. aureus infection, a situation likely
to result in emergence of rifampin-resistant S. aureus mutants
[34]. For the same reason, rifampin combinations were initially
administered to our patients intravenously in order to alleviate
interindividual variability in absorption of antibiotics, in par-
ticular, ﬂuoroquinolones [35]. Despite the use of higher daily
doses of rifampin in our patients than reported in most previous
studies [12, 14, 23, 33] and the high proportion of our patients
with chronic liver disease, rifampin had to be withdrawn in only
3( 4 . 3 % )o f6 9p a t i e n t s .
The present study has limitations due to its retrospective
design and the fact that comparisons are made on small num-
bers and therefore the risk of b error leading to the absence of
differences in populations compared is high. For instance,
among patients with MRSA infection, those given combination
therapy had a remission rate similar to that of those given
monotherapy (7/11 vs 5/6; P 5 .60), conversely to the recent
report by Ferry et al [36].
To conclude, the results of the present study suggest that pa-
tients’ ASA score signiﬁcantly affects the outcome of total hip and
knee prosthetic infections due to MSSA or MRSA and that ri-
fampin combination therapy is associated with a better outcome
for these patients, compared with other antibiotic regimens. Our
results also suggest that inadequacy of the empirical postoperative
antibiotic therapy is a risk factor for unfavorable outcome.
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